<DOC>
	<DOCNO>NCT01292174</DOCNO>
	<brief_summary>The blind safety study ibalizumab give subcutaneous injection sequentially increase dose-groups at-risk , HIV-negative , healthy volunteer . The study involve administration four total injection ibalizumab match placebo volunteer , give every week , one three dose level . Drug administration begin low dose . After 4 8 volunteer first group receive study drug injection complete 6 additional week follow-up , independent safety monitor group review available data approve initiation next high dose-group . This process repeat prior initiation 3rd high dose-group . All volunteer participate 2 separate intensive blood sample period 7 day test drug level .</brief_summary>
	<brief_title>Safety Study Ibalizumab Subcutaneous Injection Healthy Volunteers</brief_title>
	<detailed_description>The study phase 1 , randomize , double-blinded , placebo-controlled , sequential dose-escalation safety study ibalizumab at-risk HIV-negative volunteer . The study involve administration four total injection ibalizumab match placebo volunteer , give every week , one three group define : Group 1 : 120 mg sc weekly x 4 week , randomize 6:2 placebo Group 2 : 240 mg sc weekly x 4 week , randomize 6:2 placebo Group 3 : 480 mg sc weekly x 4 week , randomize 6:2 placebo Volunteers screen 42 day prior enrollment first drug administration , follow 26 week final injection . All subject expect participate two ( 2 ) intense PK sample period duration 7 day first period 14 day second period . During period ( follow Day 0 follow Week 3 ) subject daily serum concentration investigational pharmacokinetic assessment . All volunteer encourage participate optional collection genital secretion ( semen vaginal wash ) Week 4 . An independent data safety monitor board ( DSMB ) review study data four eight at-risk HIV-negative volunteer Group 1 ( 120 mg dose ) receive study drug injection complete 6 week follow-up approve escalation Group 2 ( 240 mg dose ) . The DSMB also review available study data Groups 1 , 2 four eight volunteer Group 2 receive study drug injection complete 6 week follow-up approve escalation Group 3 ( 480 mg dose ) .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Atrisk adult male female , assess medical history , physical exam , laboratory test 2 . At least 18 year age great 40 year day screen 3 . Willing comply requirement protocol available followup plan duration study 4 . In opinion principal investigator designee , understood information provide ; write informed consent need give studyrelated procedure perform 5 . Willing undergo HIV Testing counseling , receive HIV test result 6 . Agrees use barrier form contraception engage sexual activity time throughout study followup period ( male female ) two reliable form contraception , one barrier one hormonal ( e.g. , oral contraceptive pill , injectable implantable contraceptive combine diaphragm , Intra Uterine Device ( IUD ) , condom ) , must use volunteer engage sexual activity could result pregnancy ; anatomically sterile self partner ; female volunteer must willing undergo urine pregnancy test time point indicate Schedule Events Procedures 1 . Confirmed HIV1 HIV2 infection 2 . Any clinically significant abnormality history examination include history immunodeficiency autoimmune disease ; use systemic corticosteroid , immunosuppressive , anticancer , medication consider significant trial physician within last 6 month 3 . Any clinically significant acute chronic medical condition require care physician ( e.g. , diabetes , coronary artery disease , rheumatologic illness , malignancy , substance abuse ) opinion investigator would preclude participation 4 . Any laboratory value Grade 1 high accord NCI Common Toxicity Criteria 5 . Confirmed diagnosis hepatitis B ( surface antigen , HbsAg ) hepatitis C ( HCV antibody ) 6 . Current confirm STD infection 7 . Prior receipt Hepatitis A vaccine history , antihepatitis A antibody screen 8 . Pregnant , plan pregnancy trial period , lactate 9 . Receipt live attenuate vaccine ( influenza ) within 30 day vaccine within 14 day study enrollment 10 . Receipt blood transfusion blood product 6 month prior study drug administration 11 . Participation another clinical study investigational product currently within 30 day prior Screening , expect participation study 12 . History severe allergic reaction know allergy component study drug 13 . Major psychiatric illness include history schizophrenia severe psychosis , bipolar disorder require therapy , suicide attempt previous 3 year 14 . In opinion investigator , unlikely comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>HIV prevention</keyword>
</DOC>